MMP7-Induced EMT via E-cadherin/β-Catenin Drives Liver Fibrosis in Biliary Atresia: Mechanistic Insights and Research Implications

Study Background and Research Question

Biliary atresia (BA) represents a severe pediatric liver disease characterized by rapid progression of hepatic fibrosis and poor long-term survival without transplantation. While the Kasai portoenterostomy (KPE) procedure can temporarily restore bile flow, many patients experience relentless intrahepatic fibrotic progression despite early postoperative improvement. Existing adjuvant therapies, such as corticosteroids, have limited efficacy in halting fibrosis, underscoring the need for deeper mechanistic understanding and new intervention targets (reference paper). Matrix metalloproteinase 7 (MMP7), a zinc-dependent endopeptidase, has emerged as a highly specific serum biomarker in BA and is implicated in extracellular matrix remodeling as well as non-ECM substrate cleavage—including E-cadherin. Notably, sustained elevation of MMP7 post-KPE correlates with worse outcomes, but its direct mechanistic role in BA-associated liver fibrosis remained unclear. The present study addresses whether and how MMP7 drives liver fibrosis in BA, focusing on its relationship with epithelial–mesenchymal transition (EMT) and downstream molecular pathways.

Key Innovation from the Reference Study

The study's central innovation is the demonstration that MMP7 directly induces EMT in intrahepatic biliary epithelial cells (BECs) by cleaving E-cadherin, thereby promoting β-catenin nuclear translocation and activation of the canonical Wnt/β-catenin pathway. This mechanistic axis—MMP7 → E-cadherin loss → β-catenin activation—links a specific protease to a well-characterized developmental and fibrogenic signaling pathway in the context of pediatric liver disease (reference paper). Importantly, inhibition of MMP7 mitigates EMT and fibrosis in chronic BA mouse models, positioning MMP7 as both a biomarker and a mechanistic driver with therapeutic potential.

Methods and Experimental Design Insights

The researchers adopted a multi-tiered approach integrating patient samples, in vitro cell culture, bioinformatics, and animal models:

• Clinical correlation: Serum and liver tissue from BA patients were analyzed for MMP7 levels and fibrotic markers. EMT scoring in intrahepatic BECs was performed using immunohistochemistry and transcriptomic analysis.
• Bioinformatic analysis: Gene Set Enrichment Analysis (GSEA) on public GEO datasets identified EMT as the top pathway associated with MMP7 expression.
• In vitro mechanistic studies: Human intrahepatic biliary epithelial cells (HIBEpiCs) were exposed to recombinant MMP7, and the resulting effects on E-cadherin cleavage, β-catenin localization, and EMT marker expression were characterized by Western blot, immunofluorescence, and reporter assays.
• In vivo validation: Chronic BA mouse models were treated with MMP7 inhibitors, and liver tissues were analyzed for fibrotic progression and EMT markers.

This stringent, multi-modal design allowed for robust cross-validation of findings across human, cellular, and animal systems (reference paper).

Core Findings and Why They Matter

• Positive correlation between MMP7 and liver fibrosis: Patient data showed that higher intrahepatic MMP7 levels were closely associated with advanced fibrosis scores, both at the protein and transcript level.
• MMP7 drives EMT in BECs: GSEA and EMT scoring confirmed EMT as the primary MMP7-associated process in BA livers. In vitro, MMP7 exposure led to E-cadherin cleavage, loss of epithelial markers, gain of mesenchymal markers, and increased nuclear β-catenin.
• β-catenin pathway activation: MMP7-induced E-cadherin loss facilitated β-catenin nuclear translocation, indicating engagement of canonical Wnt/β-catenin signaling, a known driver of fibrogenesis.
• Therapeutic inhibition of MMP7 is anti-fibrotic: In BA mouse models, pharmacological blockade of MMP7 reduced EMT and attenuated liver fibrosis progression.

Collectively, these findings provide direct evidence that MMP7-mediated E-cadherin cleavage acts upstream of β-catenin activation to drive EMT and fibrosis in BA, revealing actionable targets in a pathway previously considered challenging to modulate in liver disease (reference paper).

Comparison with Existing Internal Articles

This study complements and extends insights from prior literature on Wnt/β-catenin pathway modulation in fibrotic diseases:

• "MMP7 Drives EMT and Liver Fibrosis via E-cadherin/β-Catenin in BA" summarizes the same mechanistic findings for a broader research audience, reinforcing the centrality of the E-cadherin/β-catenin axis in pediatric fibrosis models.
• "ICG001: Selective Wnt/β-Catenin Pathway Inhibitor for Fibrosis Research" and related articles (e.g., w18drug.com, mk-2206.com) discuss ICG001 as a potent and selective Wnt/β-catenin pathway inhibitor, particularly for CBP/β-catenin interaction disruption. These resources highlight ICG001’s utility in dissecting Wnt signaling in both cancer and fibrosis, and provide protocol guidance for integrating targeted inhibitors into translational workflows.
• The present study mechanistically bridges MMP7 proteolytic activity and Wnt/β-catenin transcriptional activation, supporting the rationale for using inhibitors like ICG001 in EMT-driven fibrosis models (mdv3100.org).

Limitations and Transferability

While the study robustly establishes the MMP7–E-cadherin–β-catenin axis in BA-associated fibrosis, several limitations warrant consideration:

• Translational gap: Most functional data relate to pediatric BA. Extrapolation to other liver fibrosis etiologies or adult populations requires further study.
• Pharmacological specificity: While MMP7 inhibitors were effective in mice, clinical translation will depend on the development of safe, selective compounds with favorable pharmacokinetics for pediatric use.
• Pathway complexity: The liver fibrosis landscape includes multiple redundant and compensatory pathways beyond Wnt/β-catenin, which may limit the efficacy of single-pathway interventions in chronic disease settings.

Nevertheless, the clear demonstration of EMT and β-catenin activation as downstream results of MMP7 proteolysis provides a strong mechanistic basis for targeted research and therapeutic development.

Protocol Parameters

• in vitro BEC EMT induction | 10–100 ng/mL recombinant MMP7 | human intrahepatic BEC culture | Recapitulates EMT and β-catenin nuclear translocation | reference paper
• Wnt/β-catenin pathway inhibition | 10 µM ICG001, 24 h | hepatic or fibrotic cell culture models | Blocks CBP/β-catenin transcriptional activity, inhibits EMT/fibrosis | product_spec
• In vivo anti-fibrotic testing | 50 mg/kg/day ICG001, subcutaneous | rodent BA/fibrosis models | Demonstrates improved cardiac and fibrotic outcomes | product_spec
• MMP7 antibody/inhibitor treatment | 1–10 mg/kg, intraperitoneal | BA mouse fibrosis model | Reduces EMT, fibrosis progression | reference paper
• Sample storage | -20°C, avoid repeated freeze/thaw | all stock solutions | Maintains compound stability | product_spec

Research Support Resources

To support the study of Wnt/β-catenin signaling and EMT-driven fibrosis, researchers can utilize well-characterized inhibitors. Notably, ICG001 (SKU A8217, APExBIO) is a selective small molecule inhibitor that antagonizes the CBP/β-catenin interaction, providing a robust tool for dissecting pathway contributions in cellular and animal models (source: product_spec). For optimal results, ICG001 is typically used at 10 µM for in vitro 24-hour treatments or at 50 mg/kg/day for in vivo studies, according to established protocols (source: product_spec). Storage at -20°C is recommended to maintain reagent stability.